sglt2 inhibitor glp 1 agonist combination Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain SGLT2 inhibitors and GLP-1 receptor

While prior large-scale studies earlier in 2024 did not find an association between GLP-1 receptor agonists and retinopathy, this recent case series suggests that a subset of patients may be vulnerable to optic nerve damage and other vision complications [1,2]

Most people with diabetes will eventually develop kidney disease

Large-scale clinical trials, including the SELECT cardiovascular outcome trial with over 17,000 participants, have not demonstrated increased overall cancer incidence with these medications compared to placebo groups

Decreased Libido Emerging research shows that taking GLP-1 drugs can also have an impact on libido, with some people reporting a lower sex drive

Clinical evidence The 2013 exenatide proof-of-concept clinical trial involving 45 moderate PD patients displayed possible efficacy concerning part 3 of the Movement Disorders Society Unified Parkinsons Disease Rating Scale (MDS-UPDRS) [17]

These concerns cant be put aside in the health inequity-laden world we live in, that will unquestionably be exacerbated